Corante

About this Author
DBL%20Hendrix%20small.png College chemistry, 1983

Derek Lowe The 2002 Model

Dbl%20new%20portrait%20B%26W.png After 10 years of blogging. . .

Derek Lowe, an Arkansan by birth, got his BA from Hendrix College and his PhD in organic chemistry from Duke before spending time in Germany on a Humboldt Fellowship on his post-doc. He's worked for several major pharmaceutical companies since 1989 on drug discovery projects against schizophrenia, Alzheimer's, diabetes, osteoporosis and other diseases. To contact Derek email him directly: derekb.lowe@gmail.com Twitter: Dereklowe

Chemistry and Drug Data: Drugbank
Emolecules
ChemSpider
Chempedia Lab
Synthetic Pages
Organic Chemistry Portal
PubChem
Not Voodoo
DailyMed
Druglib
Clinicaltrials.gov

Chemistry and Pharma Blogs:
Org Prep Daily
The Haystack
Kilomentor
A New Merck, Reviewed
Liberal Arts Chemistry
Electron Pusher
All Things Metathesis
C&E News Blogs
Chemiotics II
Chemical Space
Noel O'Blog
In Vivo Blog
Terra Sigilatta
BBSRC/Douglas Kell
ChemBark
Realizations in Biostatistics
Chemjobber
Pharmalot
ChemSpider Blog
Pharmagossip
Med-Chemist
Organic Chem - Education & Industry
Pharma Strategy Blog
No Name No Slogan
Practical Fragments
SimBioSys
The Curious Wavefunction
Natural Product Man
Fragment Literature
Chemistry World Blog
Synthetic Nature
Chemistry Blog
Synthesizing Ideas
Business|Bytes|Genes|Molecules
Eye on FDA
Chemical Forums
Depth-First
Symyx Blog
Sceptical Chymist
Lamentations on Chemistry
Computational Organic Chemistry
Mining Drugs
Henry Rzepa


Science Blogs and News:
Bad Science
The Loom
Uncertain Principles
Fierce Biotech
Blogs for Industry
Omics! Omics!
Young Female Scientist
Notional Slurry
Nobel Intent
SciTech Daily
Science Blog
FuturePundit
Aetiology
Gene Expression (I)
Gene Expression (II)
Sciencebase
Pharyngula
Adventures in Ethics and Science
Transterrestrial Musings
Slashdot Science
Cosmic Variance
Biology News Net


Medical Blogs
DB's Medical Rants
Science-Based Medicine
GruntDoc
Respectful Insolence
Diabetes Mine


Economics and Business
Marginal Revolution
The Volokh Conspiracy
Knowledge Problem


Politics / Current Events
Virginia Postrel
Instapundit
Belmont Club
Mickey Kaus


Belles Lettres
Uncouth Reflections
Arts and Letters Daily
In the Pipeline: Don't miss Derek Lowe's excellent commentary on drug discovery and the pharma industry in general at In the Pipeline

In the Pipeline

« A New Book on the Drug Industry And Its Image | Main | The Happiest Darn Drug Company in America »

December 20, 2012

CNS Drug Development Claims Another Victim

Email This Entry

Posted by Derek

Tiny Allon Therapeutics had an ambitious plan to go after progressive supranuclear palsy, a kind of progressive brain deterioration, and thence (they hoped) to other neurodegenerative disorders. The lead compound was davunetide, an oligopeptide derived from activity-dependent neuroprotective protein, ADNP.

It was a reasonable idea, but neurodegeneration is not a reasonable area. The drug has now completely wiped out in the clinic, failing both primary endpoints in its pivotal trial. This is one example of the sort of research that most people don't ever hear about, from a small company that most people will never have heard of at all. But this is the background activity of drug research (with an all-too-common outcome), and if more people were aware of it, perhaps that would be a good thing (see today's other post).

Comments (8) + TrackBacks (0) | Category: Clinical Trials | The Central Nervous System


COMMENTS

1. petros on December 20, 2012 9:37 AM writes...

Sad. So much for it being a top 10 CNS partnering opportunity!
http://www.prnewswire.com/news-releases/allon-selected-as-top-10-partnering-prospect-by-cns-experts-181353711.html

Permalink to Comment

2. bradpalm1 on December 20, 2012 10:04 AM writes...

Another "Top Projects to Watch" in the neuroscience field at this TAP conference was Naurex's GLYX-13, an interesting tetrapeptide found to be a modulator of NMDA receptors and being currently studied for treatment-resistant depression, neuropathic pain and autistic spectrum disorders. It seems to have a ketamine-like MOA without the accompanying hallucinations and has recently some good market exposure. The trick, as always, is how to get these oligopeptides into the CNS without first being broken down in the GI tract.

Permalink to Comment

3. Perdurabo on December 20, 2012 10:32 AM writes...

Quotes from the PR Newswire article are a bit ominous:
"strategic review [to] include all options for exploiting Allon's assets"
and
"The Company will also take immediate action to reduce its ongoing operating expenses including a reduction in staff."

Permalink to Comment

4. RB Woodweird on December 20, 2012 10:45 AM writes...

Somebody got hosed, eh?

"Allon Therapeutics‘ target price was increased in a recent report by Neil Maruoka of Canaccord Genuity.

“We have taken this opportunity to update our assumptions ahead of key clinical data for davunetide. With a stronger balance sheet that should allow the company to reach pivotal data, we have increased our expected probability of success for this drug to 50% from 40%. We believe that this still represents a relatively high risk profile for a pivotal study; nonetheless, we recommend that risk-tolerant investors position themselves ahead of this key potential catalyst based on a solid risk-return profile,” said Maruoka. “We value Allon using an explicit NPV model of the global opportunity for davunetide in FTD. We have revised our 12-month target to C$1.00 (from C$0.65), which continues to support our SPECULATIVE BUY recommendation."

Permalink to Comment

5. newnickname on December 20, 2012 12:03 PM writes...

Josh Chamot from the Parabon Press Release threads might want to look at the Allon Press Releases. (I've only looked at the two linked by Derek.) As biotech press releases go, there isn't very much hype. A "sad day for patients, family members, and caregivers ... so many of them held out great hope that these results would define a drug that has an impact on their disease ... we do believe that we designed the correct study and executed that study well." They didn't blame the poor results on too low a dose, an already sickened patient population, statistically insufficient data, Hurricane Sandy or anything else. They are NOT making any Big Promises about another trial with different endpoints, nothing about a 2nd generation version of the drug that will be 4x as potent or anything else. Veni, vidi, defecit.

Permalink to Comment

6. NJBiologist on December 20, 2012 12:37 PM writes...

@2 bradpalm1: "The trick, as always, is how to get these oligopeptides into the CNS without first being broken down in the GI tract."

Actually, that's one of them, and it's a big one, but another equally big one will be sidestepping the minefield of CNS side effects that has accompanied pretty much every one of the numerous attempts to modulate the NMDA receptor in the past. This problem has been widespread enough that I'd ask for multiple successful phase II trials before dismissing side effect liabilities.

Permalink to Comment

7. bradpalm1 on December 20, 2012 2:15 PM writes...

NJB: very true, although I would point to the relatively benign side effect profiles of amantadine and memantine, two structurally similar small molecule NMDA modulators which also demonstrate similar neuroprotective properties. Naurex's tetrapeptide, GLYX-13, apparently acts as a partial agonist of NMDAs receptor at the glycine binding site which is distinct from the NMDA glutamate binding site. Perhaps this helps explain its more benign profile in these Phase II trials.

I also find it intriguing that the growing recognition of NMDA modulators like amantadine and memantine (which have recently been repurposed as potential treatments for traumatic brain injury and concussions in the case of amantadine, and autism in the case of memantine) point the way to the future therapeutic potential of manipulating NMDA and AMPA receptors in these states. With the recent failure of Lilly's rigid glutamate analogs in clinical trials, elegant drugs like GLYX-13 could usher in a new exciting area of critically needed drug development.

Permalink to Comment

8. Anonymous on December 20, 2012 4:46 PM writes...

Memantine binds in the pore, not the glycine binding site. Mind you so does ketamine; memantine just comes off easier and is use dependent.

Any reason why a peptide partial agonist of the glycine site would be any better than the small molecule ones that exist? If i had to guess maybe some unknown interaction at an GluN1 splice variant that may be distributed favourably.

Permalink to Comment

POST A COMMENT




Remember Me?



EMAIL THIS ENTRY TO A FRIEND

Email this entry to:

Your email address:

Message (optional):




RELATED ENTRIES
How Not to Do It: NMR Magnets
Allergan Escapes Valeant
Vytorin Actually Works
Fatalities at DuPont
The New York TImes on Drug Discovery
How Are Things at Princeton?
Phage-Derived Catalysts
Our Most Snorted-At Papers This Month. . .